|
1
|
Diehl V: Hodgkin’s disease, from pathology
specimen to cure. N Engl J Med. 357:1968–1971. 2007.
|
|
2
|
Hasenclever D and Diehl V: A prognostic
score for advanced Hodgkin’s disease. N Engl J Med. 339:1506–1514.
1998.
|
|
3
|
Canellos GP, Anderson JR, Propert KJ, et
al: Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or
MOPP alternating with ABVD. N Engl J Med. 327:1478–1484. 1992.
|
|
4
|
Duggan DB, Petroni GR, Johnson JL, et al:
Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment
of advanced Hodgkin’s disease: report of an intergroup trial. J
Clin Oncol. 21:607–614. 2003.
|
|
5
|
Gobbi PG, Levis A, Chisesi T, et al;
Intergruppo Italiano Linfomi. ABVD versus modified stanford V
versus MOPPEBVCAD with optional and limited radiotherapy in
intermediate- and advanced-stage Hodgkin’s lymphoma: final results
of a multicenter randomized trial by the Intergruppo Italiano
Linfomi. J Clin Oncol. 23:9198–9207. 2005.PubMed/NCBI
|
|
6
|
Diehl V, Franklin J, Pfreundschuh M, et
al: Standard and increased-dose BEACOPP chemotherapy compared with
COPP-ABVD for advanced Hodgkin’s disease. Standard and
increased-dose BEACOPP. N Eng J Med. 348:2386–2395. 2003.
|
|
7
|
Diehl V and Fuchs M: Early, intermediate
and advanced Hodgkin’s lymphoma: modern treatment strategies. Ann
Oncol. 18(Suppl 9): 71–79. 2007.
|
|
8
|
Bonadonna G, Bonfante V, Viviani S, Di
Russo A, Villani F and Valagussa P: ABVD plus subtotal nodal versus
involved-field radiotherapy in early-stage Hodgkin’s disease:
long-term results. J Clin Oncol. 22:2835–2841. 2004.PubMed/NCBI
|
|
9
|
Koontz BF, Kirkpatrick JP, Clough RW, et
al: Combined-modality therapy versus radiotherapy alone for
treatment of early-stage Hodgkin’s disease: cure balanced against
complications. J Clin Oncol. 24:605–611. 2006.
|
|
10
|
Engert A, Franklin J, Eich HT, et al: Two
cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus
extended-field radiotherapy is superior to radiotherapy alone in
early favorable Hodgkin’s lymphoma: final results of the GHSG HD7
trial. J Clin Oncol. 25:3495–3502. 2007.PubMed/NCBI
|
|
11
|
Fermè C, Eghbali H, Meerwaldt JH, et al:
Chemotherapy plus involved-field radiation in early-stage Hodgkin’s
disease. EORTC-GELA H8 Trial. N Engl J Med. 357:1916–1927.
2007.
|
|
12
|
Olweny CL and Ziegler JL: Chemotherapy
plus involved-field radiation in early-stage Hodgkin’s disease. N
Engl J Med. 358:742–759. 2008.
|
|
13
|
Laskar S, Gupta T, Vimal S, et al:
Consolidation radiation after complete remission in Hodgkin’s
disease following six cycles of doxorubicin, bleomycin,
vinblastine, and dacarbazine chemotherapy: is there a need? J Clin
Oncol. 22:62–68. 2004.
|
|
14
|
Straus DJ, Portlock CS, Qin J, et al:
Results of a prospective randomized clinical trial of doxorubicin,
bleomycin, vinblastine, and dacarbazine (ABVD) followed by
radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA
nonbulky Hodgkin disease. Blood. 104:3483–3489. 2004. View Article : Google Scholar
|
|
15
|
Meyer RM, Gospodarowicz MK, Connors JM, et
al: Randomized comparison of ABVD chemotherapy with a strategy that
includes radiation therapy in patients with limited-stage Hodgkin’s
lymphoma: National Cancer Institute of Canada Clinical Trials Group
and the Eastern Cooperative Oncology Group. J Clin Oncol.
23:4634–4642. 2005.PubMed/NCBI
|
|
16
|
Gospodarowicz MK and Meyer RM: The
management of patients with limited-stage classical Hodgkin
lymphoma. ASH 2006 Educational Book. pp. 255–258. 2006, PubMed/NCBI
|
|
17
|
Canellos GP, Abramson JS, Fisher DC and
LaCasce AS: Treatment of favourable, limited-stage Hodgkin’s
lymphoma with chemotherapy without consolidation by radiation
therapy. J Clin Oncol. 28:1611–1615. 2010.
|
|
18
|
Viviani S, Di Nicola M, Bonfante V, et al:
Long-term results of high-dose chemotherapy with autologous bone
marrow or peripheral stem cell transplant as first salvage
treatment for relapsed or refractory Hodgkin lymphoma: a single
institution experience. Leuk Lymphoma. 51:1251–1259. 2010.
View Article : Google Scholar
|
|
19
|
Zinzani PL, Tani M, Molinari AL, Stefoni
V, Zuffa E, Alinari L, Gabriele A, Bonifazi F, Salvucci M, Tura S
and Baccarani M: Ifosfamide, epirubicin and etoposide regimen as
salvage and mobilizing therapy for relapsed/refractory lymphoma
patients. Haematologica. 87:816–821. 2002.PubMed/NCBI
|
|
20
|
Clavio M, Garrone A, Pierri I, Michelis
GL, Balocco M, Albarello A, Varaldo R, Canepa P, Miglino M,
Ballerini F, Canepa L and Gobbi M: Ifosfamide, epirubicin,
etoposide (IEV) and autologous peripheral blood progenitor cell
transplant: a feasible and effective salvage treatment for lymphoid
malignancies. Oncol Rep. 14:933–940. 2005.
|
|
21
|
Santoro A, Magagnoli M, Spina M, Pinotti
G, Siracusano L, Michieli M, Nozza A, Sarina B, Morenghi E,
Castagna L, Tirelli U and Balzarotti M: Ifosfamide, gemcitabine,
and vinorelbine: a new induction regimen for refractory and
relapsed Hodgkin’s lymphoma. Haematologica. 92:35–41.
2007.PubMed/NCBI
|
|
22
|
Hoppe RT: Hodgkin’s disease: complications
of therapy and excess mortality. Ann Oncol. 8(Suppl 1): 115–118.
1997.
|
|
23
|
Jaffe ES, Lee Harris N, Stein H and
Vardiman JW: World Health Organization Classification of Tumors.
Pathology and Genetics of Tumors of Haematopoietic and Lymphoid
Tissues. IARC Press; Lyon: 2001
|
|
24
|
Brusamolino E, Bacigalupo A, Barosi G, et
al: Classical Hodgkin’s lymphoma in adults: guidelines of the
Italian Society of Hematology, the Italian Society of Experimental
Hematology, and the Italian Group for Bone Marrow Transplantation
on initial work-up, management, and follow-up. Haematologica.
94:550–565. 2009.
|
|
25
|
Provencio M, Salas C, Millan I, Cantos B,
Sanchez A and Bellas C: Late relapses in Hodgkin Lymphoma: a
clinical and immunochemistry study. Leuk Lymphoma. 51:1686–1691.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Walker A, Schoenfeld ER, Lowman JT,
Mettlin CJ, MacMillan J and Grufferman S: Survival of the older
patient compared with the younger patient with Hodgkin’s disease.
Influence of histologic type, staging, and treatment. Cancer.
65:1635–1640. 1990.
|
|
27
|
Diaz-Pavon JR, Cabanillas F, Majlis A and
Hagemeister FB: Outcome of Hodgkin’s disease in elderly patients.
Hematol Oncol. 13:19–27. 1995.
|
|
28
|
Gallamini A: Positron emission tomography
scanning: a new paradigm for the management of Hodgkin’s lymphoma.
Haematologica. 95:1046–1048. 2010.
|
|
29
|
Olcese F, Clavio M, Rossi E, et al: The
addition of radiotherapy to chemotherapy does not improve outcome
of early stage Hodgkin’s lymphoma patients: a retrospective
long-term follow-up analysis of a regional Italian experience. Ann
Hematol. 88:855–861. 2009.
|
|
30
|
Ghalibafian M, Beaudre A and Girinsky T:
Heart and coronary artery protection in patients with mediastinal
Hodgkin lymphoma treated with intensity-modulated radiotherapy:
dose constraints to virtual volumes or to organs at risk? Radiother
Oncol. 87:82–88. 2008.
|
|
31
|
Travis LB: Evaluation of the risk of
therapy-associated complications in survivors of Hodgkin lymphoma.
Hematology Am Soc Hematol Educ Program. 2007.192–196
|
